DiaMedica Therapeutics
DMAC
DMAC
28 hedge funds and large institutions have $3.92M invested in DiaMedica Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0.02% less ownership
Funds ownership: 9.57% → 9.55% (-0.02%)
73% less call options, than puts
Call options by funds: $3K | Put options by funds: $11K
Holders
28
Holding in Top 10
–
Calls
$3K
Puts
$11K
Top Buyers
| 1 | +$53K | |
| 2 | +$17.1K | |
| 3 | +$6.8K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$4.45K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.41K |
Top Sellers
| 1 | -$44K | |
| 2 | -$31K | |
| 3 | -$12K | |
| 4 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
-$7.54K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.43K |